We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Researchers Discover Antibody that Blocks Novel Coronavirus SARS-CoV-2 Infection in Cells

By HospiMedica International staff writers
Posted on 05 May 2020
Print article
Illustration
Illustration
A group of researchers have identified a fully human monoclonal antibody that prevents the SARS-CoV-2 (COVID-19) virus from infecting cultured cells, marking the initial step towards developing a fully human antibody to treat or prevent the respiratory disease caused by the novel coronavirus.

The researchers at Utrecht University (Utrecht, the Netherlands), Erasmus Medical Center (Rotterdam, the Netherlands) and Harbour BioMed {(HBM) Cambridge, MA, USA} have published a paper titled, “A human monoclonal antibody blocking SARS-VoV-2 Infection” in Nature Communications. According to the researchers, the antibody binds to a domain that is conserved in both SARS-CoV and SARS-CoV-2, explaining its ability to neutralize both viruses. Conventional therapeutic antibodies are first developed in other species and then must undergo additional work to ‘humanize’ them. The antibody was generated using Harbour BioMed’s H2L2 transgenic mouse technology.

“This cross-neutralizing feature of the antibody is very interesting and suggests it may have potential in mitigation of diseases caused by future-emerging related coronaviruses,” said Berend-Jan Bosch, PhD, Associate Professor, Research leader at Utrecht University, and co-lead author of the study.

“This discovery provides a strong foundation for additional research to characterize this antibody and begin development as a potential COVID-19 treatment,” said Frank Grosveld, PhD, co-lead author on the study, Academy Professor of Cell Biology, Erasmus Medical Center, Rotterdam and Founding Chief Scientific Officer at Harbour BioMed. “The antibody used in this work is ‘fully human,’ allowing development to proceed more rapidly and reducing the potential for immune-related side effects.”

“This is groundbreaking research,” said Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of HBM. “Much more work is needed to assess whether this antibody can protect or reduce the severity of disease in humans. We expect to advance development of the antibody with partners. We believe our technology can contribute to addressing this most urgent public health need and we are pursuing several other research avenues.”

Related Links:
Utrecht University
Erasmus Medical Center
Harbour BioMed


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Flocked Fiber Swabs
Puritan® patented HydraFlock®
New
Fixed Height Patient Trolley
GT1501
New
40/80-Slice CT System
uCT 528

Print article

Channels

Critical Care

view channel
Image: AI could tackle the huge problem of antimicrobial resistance in intensive care (Photo courtesy of 123RF)

AI Provides Same-Day Prediction of Bloodstream Infection and Antimicrobial Resistance in ICU Patients

Antimicrobial resistance, which refers to the ability of microorganisms to develop defenses against treatments, presents a significant challenge to global healthcare. Infections in the bloodstream can... Read more

Surgical Techniques

view channel
Image: Robots could help close surgeons’ skill gaps and improve patient outcomes (Photo courtesy of Intuitive Surgical)

Robots to Play Larger Role in Surgery Due to Recent AI Developments

Surgeons commonly utilize robots for specific minimally invasive procedures, yet humans still dictate nearly all movements of these machines. Recent advancements in artificial intelligence (AI) and robotics... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.